Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144


Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.

Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, Algazi AP, Damian S, Hong RL, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B.

Am J Clin Oncol. 2018 Feb 21. doi: 10.1097/COC.0000000000000429. [Epub ahead of print]


Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP.

Br J Cancer. 2018 Feb 6;118(3):344-352. doi: 10.1038/bjc.2017.436. Epub 2018 Jan 16.


Fluorescence-guided surgery for cancer patients: a proof of concept study on human xenografts in mice and spontaneous tumors in pets.

Mery E, Golzio M, Guillermet S, Lanore D, Naour AL, Thibault B, Tilkin-Mariamé AF, Bellard E, Delord JP, Querleu D, Ferron G, Couderc B.

Oncotarget. 2017 Nov 30;8(65):109559-109574. doi: 10.18632/oncotarget.22728. eCollection 2017 Dec 12.


Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2017 Nov 21. pii: S1525-7304(17)30314-5. doi: 10.1016/j.cllc.2017.11.002. [Epub ahead of print]


Comparison of variable selection methods for high-dimensional survival data with competing events.

Gilhodes J, Zemmour C, Ajana S, Martinez A, Delord JP, Leconte E, Boher JM, Filleron T.

Comput Biol Med. 2017 Dec 1;91:159-167. doi: 10.1016/j.compbiomed.2017.10.021. Epub 2017 Oct 20.


First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.

Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A.

Eur J Cancer. 2017 Nov;86:240-247. doi: 10.1016/j.ejca.2017.09.009. Epub 2017 Oct 19.


[Observational study of outpatient unit duration of stay depending on the route of administration (intravenous vs subcutaneous) for a targeted therapy].

Despiau F, Zagala Y, Delord JP, Montastruc M, Lacaze JL, Ferrand R, Bombail M.

Bull Cancer. 2017 Oct;104(10):869-874. doi: 10.1016/j.bulcan.2017.08.007. Epub 2017 Oct 13. French.


An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.

Temam S, Spicer J, Farzaneh F, Soria JC, Oppenheim D, McGurk M, Hollebecque A, Sarini J, Hussain K, Soehrman Brossard S, Manenti L, Evers S, Delmar P, Di Scala L, Mancao C, Feuerhake F, Andries L, Ott MG, Passioukov A, Delord JP.

Ann Oncol. 2017 Nov 1;28(11):2827-2835. doi: 10.1093/annonc/mdx489.


Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.

Ravaud A, Gomez-Roca C, Picat MQ, Digue L, Chevreau C, Gimbert A, Chauzit E, Sitta R, Cornelis F, Asselineau J, Aziza R, Daste A, Quemener C, Baud J, Bikfalvi A, Pedenon-Périchout D, Doussau A, Molimard M, Delord JP.

Eur J Cancer. 2017 Nov;85:39-48. doi: 10.1016/j.ejca.2017.07.031. Epub 2017 Sep 5.


Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

Aboudaram A, Modesto A, Chaltiel L, Gomez-Roca C, Boulinguez S, Sibaud V, Delord JP, Chira C, Delannes M, Moyal E, Meyer N.

Melanoma Res. 2017 Oct;27(5):485-491. doi: 10.1097/CMR.0000000000000386.


Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R.

Clin Cancer Res. 2017 Sep 15;23(18):5339-5348. doi: 10.1158/1078-0432.CCR-16-2923. Epub 2017 Jun 13.


Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.

Bétrian S, Gomez-Roca C, Vigarios E, Delord JP, Sibaud V.

JAMA Dermatol. 2017 Jul 1;153(7):723-725. doi: 10.1001/jamadermatol.2017.0500. No abstract available.


A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM.

Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.


A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.

Ravaud A, de la Fouchardière C, Caron P, Doussau A, Do Cao C, Asselineau J, Rodien P, Pouessel D, Nicolli-Sire P, Klein M, Bournaud-Salinas C, Wemeau JL, Gimbert A, Picat MQ, Pedenon D, Digue L, Daste A, Catargi B, Delord JP.

Eur J Cancer. 2017 May;76:110-117. doi: 10.1016/j.ejca.2017.01.029. Epub 2017 Mar 20.


Development of Photoonycholysis with Vandetanib Therapy.

Negulescu M, Zerdoud S, Boulinguez S, Tournier E, Delord JP, Baran R, Sibaud V.

Skin Appendage Disord. 2017 Jan;2(3-4):146-151. doi: 10.1159/000452425. Epub 2016 Nov 3.


Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine.

Husseini F, Delord JP, Fournel-Federico C, Guitton J, Erbs P, Homerin M, Halluard C, Jemming C, Orange C, Limacher JM, Kurtz JE.

Ann Oncol. 2017 Jan 1;28(1):169-174. doi: 10.1093/annonc/mdw440.


Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C.

Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666.


A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr.

J Thorac Oncol. 2017 Mar;12(3):556-566. doi: 10.1016/j.jtho.2016.11.2218. Epub 2016 Nov 19.


Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J.

J Clin Oncol. 2017 Jan 10;35(2):157-165. Epub 2016 Nov 21.


Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Betrian S, Ysebaert L, Heider KH, Delord JP, Fournié JJ, Quillet-Mary A.

Blood Cancer J. 2016 Nov 11;6(11):e496. doi: 10.1038/bcj.2016.106. No abstract available.


[Subgroup analysis and forest plots: Limitations and interests].

Filleron T, Gilhodes J, Delord JP, Cabarrou B.

Bull Cancer. 2017 Jan;104(1):92-100. doi: 10.1016/j.bulcan.2016.09.023. Epub 2016 Nov 4. Review. French.


[The role of the bed manager nurse in medical oncology].

Despiau F, Bombail M, Marion J, Delord JP.

Soins. 2016 Oct;61(809):18-21. doi: 10.1016/j.soin.2016.08.002. French.


How to report toxicity associated with targeted therapies?

Cabarrou B, Boher JM, Bogart E, Tresch-Bruneel E, Penel N, Ravaud A, Escudier B, Mahier Ait-Oukhatar C, Delord JP, Roché H, Filleron T.

Ann Oncol. 2016 Aug;27(8):1633-8. doi: 10.1093/annonc/mdw218. Epub 2016 May 23.


Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.

Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP.

Curr Opin Oncol. 2016 Jul;28(4):254-63. doi: 10.1097/CCO.0000000000000290. Review.


Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung.

Ung M, Rouquette I, Filleron T, Taillandy K, Brouchet L, Bennouna J, Delord JP, Milia J, Mazières J.

Clin Lung Cancer. 2016 Sep;17(5):391-397. doi: 10.1016/j.cllc.2016.03.001. Epub 2016 Mar 17.


Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer.

Cabarrou B, Belin L, Somda SM, Falcou MC, Pierga JY, Kirova Y, Delord JP, Asselain B, Filleron T.

Breast Cancer Res Treat. 2016 Apr;156(3):577-585. doi: 10.1007/s10549-016-3789-9. Epub 2016 Apr 13.


Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.

Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, Uro-Coste E, de Braud F, Pelosi G, French CA.

Cancer Discov. 2016 May;6(5):492-500. doi: 10.1158/2159-8290.CD-15-1335. Epub 2016 Mar 14.


[Value of neck dissection before definitive radiation therapy for locoregionally advanced squamous cell carcinoma of the head and neck].

Modesto A, Sarini J, Benlyazid A, Ouali M, Laprie A, Graff P, Vergez S, Uro-Coste E, Fauquet I, Delord JP, Rives M.

Cancer Radiother. 2016 Feb;20(1):18-23. doi: 10.1016/j.canrad.2015.09.008. Epub 2015 Dec 31. French.


Primary care physicians and oncologists are partners in cancer announcement.

Rougé Bugat ME, Omnes C, Delpierre C, Escourrou E, Boussier N, Oustric S, Delord JP, Bauvin E, Grosclaude P.

Support Care Cancer. 2016 Jun;24(6):2473-9. doi: 10.1007/s00520-015-3049-2. Epub 2015 Dec 14.


Factors Associated with Severe Leptospirosis, Martinique, 2010-2013.

Hochedez P, Theodose R, Olive C, Bourhy P, Hurtrel G, Vignier N, Mehdaoui H, Valentino R, Martinez R, Delord JM, Herrmann C, Lamaury I, Césaire R, Picardeau M, Cabié A.

Emerg Infect Dis. 2015 Dec;21(12):2221-4. doi: 10.3201/eid2112.141099.


Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

Khalifa J, Ouali M, Chaltiel L, Le Guellec S, Le Cesne A, Blay JY, Cousin P, Chaigneau L, Bompas E, Piperno-Neumann S, Bui-Nguyen B, Rios M, Delord JP, Penel N, Chevreau C.

BMC Cancer. 2015 Oct 15;15:700. doi: 10.1186/s12885-015-1697-8.


F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

Thibault B, Clement E, Zorza G, Meignan S, Delord JP, Couderc B, Bailly C, Narducci F, Vandenberghe I, Kruczynski A, Guilbaud N, Ferré P, Annereau JP.

Cancer Lett. 2016 Jan 1;370(1):10-8. doi: 10.1016/j.canlet.2015.09.006. Epub 2015 Sep 25.


[Nurse telephone support at home during chemotherapy].

Despiau F, Bombail M, Leches C, Montastruc M, Gladieff L, Delord JP.

Rev Infirm. 2015 Aug-Sep;(213):37-9. doi: 10.1016/j.revinf.2015.06.011. French.


Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators.

Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.


Acute skin reaction suggestive of pembrolizumab-induced radiosensitization.

Sibaud V, David I, Lamant L, Resseguier S, Radut R, Attal J, Meyer N, Delord JP.

Melanoma Res. 2015 Dec;25(6):555-8. doi: 10.1097/CMR.0000000000000191.


Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.

Thomas F, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, Bonadona A, Penel N, Goncalves A, Delord JP, Toulas C, Chatelut E.

Clin Pharmacol Ther. 2016 Feb;99(2):235-42. doi: 10.1002/cpt.210. Epub 2015 Nov 10.


CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.

Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D.

Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12.


Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.

Sibaud V, Tournier E, Roché H, Del Giudice P, Delord JP, Hubiche T.

Clin Exp Dermatol. 2016 Jan;41(1):34-7. doi: 10.1111/ced.12675. Epub 2015 May 11.


Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.

Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A.

Oncotarget. 2015 May 20;6(14):12796-808.


T-DM1 extravasation: first description.

Sibaud V, Nougarolis S, Borjesson C, Gangloff D, Delord JP, Pompa V, Saintenac D, Roche H.

J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1235-6. doi: 10.1111/jdv.13164. Epub 2015 Apr 16. No abstract available.


Guideline sheets on the side effects of anticancer drugs are useful for general practitioners.

Rouge-Bugat ME, Lassoued D, Bacrie J, Boussier N, Delord JP, Oustric S, Bauvin E, Lapeyre-Mestre M, Bertucci F, Grosclaude P.

Support Care Cancer. 2015 Dec;23(12):3473-80. doi: 10.1007/s00520-015-2705-x. Epub 2015 Mar 27.


CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, Verheul H, Le Tourneau C, Delord JP, van Herpen C, Mahalingam D, Coveler AL, Meresse V, Weigand S, Runza V, Cannarile M.

Clin Cancer Res. 2015 Jun 15;21(12):2753-62. doi: 10.1158/1078-0432.CCR-14-2141. Epub 2015 Mar 11.


Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.

Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P.

Ann Oncol. 2015 May;26(5):1005-11. doi: 10.1093/annonc/mdv031. Epub 2015 Feb 2.


A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.

Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J.

Br J Cancer. 2015 Feb 17;112(4):650-9. doi: 10.1038/bjc.2014.653. Epub 2015 Jan 27.


Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.

Vigarios E, Lamant L, Delord JP, Fricain JC, Chevreau C, Barrés B, Gomez-Roca C, Boulanger M, Sibaud V.

Br J Dermatol. 2015 Jun;172(6):1680-2. doi: 10.1111/bjd.13610. Epub 2015 Apr 19. No abstract available.


T-DM1-related telangiectasias: a potential role in secondary bleeding events.

Sibaud V, Vigarios E, Combemale P, Lamant L, Lacouture ME, Lacaze JL, Dalenc F, Delord JP.

Ann Oncol. 2015 Feb;26(2):436-7. doi: 10.1093/annonc/mdu533. Epub 2014 Nov 17. No abstract available.


Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?

Dercle L, Chisin R, Ammari S, Gillebert Q, Ouali M, Jaudet C, Delord JP, Dierickx L, Zerdoud S, Schlumberger M, Courbon F.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):397-408. doi: 10.1007/s00259-014-2938-9. Epub 2014 Nov 1.


Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer: minimization of late dysphagia without jeopardizing tumor control.

Modesto A, Laprie A, Vieillevigne L, Graff P, Sarini J, Vergez S, Delord JP, Farenc JC, Vigarios E, Filleron T, Rives M.

Strahlenther Onkol. 2015 Mar;191(3):225-33. doi: 10.1007/s00066-014-0767-1. Epub 2014 Nov 1.


[Cetuximab cutaneous adverse drug reactions: a marker of efficacy for metastatic colorectal cancer and head-neck cancer?].

Soussan-Dahan M, Lapeyre-Mestre M, Bondon-Guitton E, Delord JP, Despas F.

Therapie. 2014 Nov-Dec;69(6):499-507. doi: 10.2515/therapie/2014060. Epub 2014 Oct 1. French.


Supplemental Content

Loading ...
Support Center